Your browser doesn't support javascript.
loading
Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.
Harvala, Heli; Mehew, Jennifer; Robb, Matthew L; Ijaz, Samreen; Dicks, Steven; Patel, Monika; Watkins, Nicholas; Simmonds, Peter; Brooks, Tim; Johnson, Rachel; Gopal, Robin; Roberts, David J; Zambon, Maria.
Afiliação
  • Harvala H; Microbiology Services, NHS Blood and Transplant, London, United Kingdom.
  • Mehew J; Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom.
  • Robb ML; Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom.
  • Ijaz S; Virology Reference Department, National Infection Service, Public Health England, Colindale Avenue, London, United Kingdom.
  • Dicks S; Microbiology Services, NHS Blood and Transplant, London, United Kingdom.
  • Patel M; Virology Reference Department, National Infection Service, Public Health England, Colindale Avenue, London, United Kingdom.
  • Watkins N; High Containment Microbiology, National Infection Service, Public Health England, Colindale Avenue, London, United Kingdom.
  • Simmonds P; NHS Blood and Transplant, Cambridge, United Kingdom.
  • Brooks T; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Johnson R; Rare & Imported Pathogens Laboratory, Public Health England, Porton Down, United Kingdom.
  • Gopal R; Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom.
  • Roberts DJ; High Containment Microbiology, National Infection Service, Public Health England, Colindale Avenue, London, United Kingdom.
  • Zambon M; NHS Blood and Transplant, Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
Euro Surveill ; 25(28)2020 Jul.
Article em En | MEDLINE | ID: mdl-32700670
ABSTRACT
Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Anticorpos Neutralizantes / Betacoronavirus Tipo de estudo: Diagnostic_studies Limite: Adolescent / Adult / Aged / Humans / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Anticorpos Neutralizantes / Betacoronavirus Tipo de estudo: Diagnostic_studies Limite: Adolescent / Adult / Aged / Humans / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article